Abstract
BackgroundThe influence of isoform A of reticulon-4 (Nogo-A), also known as neurite outgrowth inhibitor, on primary brain tumor development was reported. Therefore the aim was the evaluation of Nogo-A concentrations in cerebrospinal fluid (CSF) and serum of brain tumor patients compared with non-tumoral individuals.ResultsAll serum results, except for two cases, obtained both in brain tumors and non-tumoral individuals, were below the lower limit of ELISA detection. Cerebrospinal fluid Nogo-A concentrations were significantly lower in primary brain tumor patients compared to non-tumoral individuals. The univariate linear regression analysis found that if white blood cell count increases by 1 × 103/μL, the mean cerebrospinal fluid Nogo-A concentration value decreases 1.12 times. In the model of multiple linear regression analysis predictor variables influencing cerebrospinal fluid Nogo-A concentrations included: diagnosis, sex, and sodium level. The mean cerebrospinal fluid Nogo-A concentration value was 1.9 times higher for women in comparison to men. In the astrocytic brain tumor group higher sodium level occurs with lower cerebrospinal fluid Nogo-A concentrations. We found the opposite situation in non-tumoral individuals.ConclusionsUnivariate linear regression analysis revealed, that cerebrospinal fluid Nogo-A concentrations change in relation to white blood cell count. In the created model of multiple linear regression analysis we found, that within predictor variables influencing CSF Nogo-A concentrations were diagnosis, sex, and sodium level. Results may be relevant to the search for cerebrospinal fluid biomarkers and potential therapeutic targets in primary brain tumor patients.Materials and methodsNogo-A concentrations were tested by means of enzyme-linked immunosorbent assay (ELISA).
Highlights
Aside from its role in neurite growth isoform A of reticulon-4 (Nogo-A) has a variety of other functions, e.g. participation in neuronal stem cells differentiation, inhibition of angiogenesis, microglial activity [1].The role and expression of Nogo-A in brain tumors were studied by several authors [2,3,4,5,6,7]
Cerebrospinal fluid Nogo-A concentrations were significantly lower in primary brain tumor patients compared to non-tumoral individuals
Univariate linear regression analysis revealed, that cerebrospinal fluid Nogo-A concentrations change in relation to white blood cell count
Summary
The role and expression of Nogo-A in brain tumors were studied by several authors [2,3,4,5,6,7]. The authors revealed lower migration and invasion abilities of the U87-Nogo-A cells expressing Nogo-A in comparison to control U87MG-E cells not expressing this protein [5]. That Nogo-66 may have inhibiting abilities on the adhesion and migration of human glioma cells in vitro. This effect may be mediated via the NgR (receptor for Nogo-66), as they revealed that treatment of U87MG cells with NgR antibodies resulted in lowering their potential for adhesion and migration [7]. The aim was the evaluation of Nogo-A concentrations in cerebrospinal fluid (CSF) and serum of brain tumor patients compared with non-tumoral individuals
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
